Rein Therapeutics Inc (NASDAQ: RNTX)’s stock price has dropped by -20.48 in relation to previous closing price of 2.49. Nevertheless, the company has seen a loss of -10.00% in its stock price over the last five trading days.
Is It Worth Investing in Rein Therapeutics Inc (NASDAQ: RNTX) Right Now?
The stock has a 36-month beta value of 2.25. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNTX is 19.52M, and at present, short sellers hold a 1.00% of that float. On January 31, 2025, the average trading volume of RNTX was 105.60K shares.
RNTX’s Market Performance
RNTX stock saw a decrease of -10.00% in the past week, with a monthly decline of -11.21% and a quarterly a decrease of -50.75%. The volatility ratio for the week is 23.36%, and the volatility levels for the last 30 days are 13.55% for Rein Therapeutics Inc (RNTX). The simple moving average for the past 20 days is -7.41% for RNTX’s stock, with a -34.57% simple moving average for the past 200 days.
Analysts’ Opinion of RNTX
Many brokerage firms have already submitted their reports for RNTX stocks, with Rodman & Renshaw repeating the rating for RNTX by listing it as a “Buy.” The predicted price for RNTX in the upcoming period, according to Rodman & Renshaw is $8 based on the research report published on January 28, 2025 of the current year 2025.
Jefferies gave a rating of “Buy” to RNTX, setting the target price at $20 in the report published on July 24th of the previous year.
RNTX Trading at -12.41% from the 50-Day Moving Average
After a stumble in the market that brought RNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.32% of loss for the given period.
Volatility was left at 13.55%, however, over the last 30 days, the volatility rate increased by 23.36%, as shares sank -14.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.18% lower at present.
During the last 5 trading sessions, RNTX fell by -10.00%, which changed the moving average for the period of 200-days by -67.75% in comparison to the 20-day moving average, which settled at $2.14. In addition, Rein Therapeutics Inc saw -13.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNTX starting from WINDSOR JAMES BRIAN, who purchase 400 shares at the price of $2.24 back on Dec 05 ’24. After this action, WINDSOR JAMES BRIAN now owns 239 shares of Rein Therapeutics Inc, valued at $898 using the latest closing price.
UNIVERSITY OF TEXAS/TEXAS AM I, the 10% Owner of Rein Therapeutics Inc, sale 4,707 shares at $3.25 during a trade that took place back on Jun 17 ’24, which means that UNIVERSITY OF TEXAS/TEXAS AM I is holding 1,746,549 shares at $15,298 based on the most recent closing price.
Stock Fundamentals for RNTX
Equity return is now at value -54.95, with -49.97 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.30.
Conclusion
To sum up, Rein Therapeutics Inc (RNTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
